Clinical Trials Directory

Trials / Completed

CompletedNCT01765933

Pharmacokinetic Effects of Oral DMAA

Pharmacokinetic and Physiological Effects of Oral DMAA Administration

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
8 (actual)
Sponsor
University of Memphis · Academic / Other
Sex
Male
Age
18 Years – 40 Years
Healthy volunteers
Accepted

Summary

1,3-dimethylamylamine (DMAA) has become increasingly popular as a component of dietary supplements. It is also used within "party pills," often in conjunction with alcohol and other drugs, and has been associated with untoward effects when abused at high dosages. To our knowledge, no studies have been conducted to determine the combined pharmacokinetic profile and physiologic responses of DMAA. To conclude on the safety profile of DMAA based solely on case reports would be problematic, in particular when accepting testimony from patients in uncontrolled environment, potentially under the influence of alcohol and other drugs. This is especially true in light of the fact that no prospective studies have shown these effects. Hence, the intent of the present study was to determine the pharmacokinetic profile of a single 25mg oral dosage of DMAA alone through 24 hours post-ingestion. This represents a typical dosage within one serving of many popular dietary supplements containing DMAA.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTDMAAno placebo

Timeline

Start date
2012-04-01
Primary completion
2012-05-01
Completion
2012-12-01
First posted
2013-01-11
Last updated
2013-01-11

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01765933. Inclusion in this directory is not an endorsement.